Safety & Efficacy of NABOTA in Treatment of Essential Blepharospasm

See also
Status	Clinical Trial	Phase
Completed	`NCT01686061` - Blepharospasm Patient Survey for Patients With Blepharospasm
Completed	`NCT00535938` - MDs on Botox Utility (MOBILITY)	N/A
Recruiting	`NCT05027997` - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm	Phase 2
Terminated	`NCT03263000` - Photic Blink Reflex in People With Blepharospasm and Increased Blinking
Completed	`NCT03938363` - Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia	N/A
Completed	`NCT00406367` - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm	Phase 3
Completed	`NCT00682760` - Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm	Phase 3
Completed	`NCT00210431` - Post Marketing Surveillance Study of Dysport
Completed	`NCT05103202` - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Completed	`NCT04423341` - Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm	Phase 2/Phase 3
Completed	`NCT03269123` - A Mechanical Device for Blepharospasm	N/A
Completed	`NCT00411255` - Brain Stimulation to Treat Blepharospasm or Meige Syndrome	Phase 2
Completed	`NCT00500799` - Brain Changes in Blepharospasm	N/A
Completed	`NCT00761592` - Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm	Phase 4
Completed	`NCT00001784` - Mexiletine for the Treatment of Focal Dystonia	Phase 2
Recruiting	`NCT04939909` - Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm	Early Phase 1
Completed	`NCT03508882` - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm	Phase 4
Completed	`NCT01814774` - A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm	N/A
Completed	`NCT00234507` - Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm	Phase 2
Recruiting	`NCT05618470` - Wumeiwan Jiawei Fang Use in Patients With Blepharospasm	Phase 2/Phase 3

NCT number	NCT02947815
Study type	Interventional
Source	Daewoong Pharmaceutical Co. LTD.
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	October 2016
Completion date	January 2018

Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms